Hello chazzledazzle, here are the answers to y

Hello chazzledazzle,

here are the answers to your questions:

Quote:

---

Do I recall correctly that you posted a few days ago that a friend who is a big-time analysts was going to help you do this (by Wednesday, so congrats on Monday)? If so, can you describe the relationship and the credentials?

---

Yes, he is a Family friend and he helped getting figures together, sorted and fine tuned it with my database, that was already gathered.

He is an Investment Broker and consultant (advisor) for one of the biggest European banks and studied International Business in Berlin, London and Beijing.

Quote:

---

can you describe the methodology used when determining that revenue would be created for a new indication by a certain time. For instance, (forgive me if my example isn’t exactly as you’ve written, but) ‘Alzheimer’s disease is approved and makes xxx revenue in 2023.’

---

Methodology is considered as following:

In 2021 share count increase as dilution considered of 100 mn shares with the price of pps appr. $ 25-35, that gives Cytodyn around $ 2,5-3 bn for the several indications to be successful in clinical trials over the next 2-3 years.

Methodology for Alzheimer as example:

Alzheimer worldwide (revenue; CYDY revenue; market share in %) $ bn.
Year rev. ww CYDY in %
2023 $11,33 $0,22 3
2024 $14,16 $0,45 5
2025 $17,70 $0,79 7
2026 $18,94 $1,42 10
2027 $20,26 $1,77 10
2028 $21,68 $1,89 10
2029 $23,20 $2,03 10
2030 $24,83 $2,17 10
2031 $26,56 $2,32 10
2032 $28,42 $2,48 10
2033 $30,41 $2,66 10

Hope this answers your questions.

If you have a different approach, would like to hear your opinion and suggestions to fine tune the database.

Greetings Sunny